Hologic, Inc. $HOLX Shares Sold by Groupama Asset Managment

Groupama Asset Managment cut its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 32.8% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 14,739 shares of the medical equipment provider’s stock after selling 7,203 shares during the period. Groupama Asset Managment’s holdings in Hologic were worth $995,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Hologic by 10.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,776 shares of the medical equipment provider’s stock worth $2,395,000 after purchasing an additional 3,520 shares during the period. Empowered Funds LLC lifted its stake in shares of Hologic by 27.7% in the 1st quarter. Empowered Funds LLC now owns 17,494 shares of the medical equipment provider’s stock worth $1,081,000 after acquiring an additional 3,790 shares during the period. Allworth Financial LP boosted its holdings in shares of Hologic by 120.3% in the second quarter. Allworth Financial LP now owns 1,511 shares of the medical equipment provider’s stock valued at $98,000 after acquiring an additional 825 shares in the last quarter. Creative Planning boosted its holdings in shares of Hologic by 229.8% in the second quarter. Creative Planning now owns 73,122 shares of the medical equipment provider’s stock valued at $4,765,000 after acquiring an additional 50,953 shares in the last quarter. Finally, Nomura Asset Management Co. Ltd. increased its stake in shares of Hologic by 2.5% during the second quarter. Nomura Asset Management Co. Ltd. now owns 137,622 shares of the medical equipment provider’s stock worth $8,967,000 after acquiring an additional 3,393 shares during the period. 94.73% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

HOLX has been the subject of a number of recent analyst reports. Argus downgraded shares of Hologic from a “buy” rating to a “hold” rating in a research report on Monday, January 12th. Evercore cut Hologic from an “outperform” rating to an “in-line” rating and dropped their target price for the stock from $79.00 to $78.00 in a research report on Monday, January 5th. Weiss Ratings reissued a “hold (c)” rating on shares of Hologic in a research note on Wednesday, January 28th. Finally, BNP Paribas Exane cut Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 price target for the company. in a report on Friday, November 21st. Two investment analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the stock. According to data from MarketBeat, Hologic has an average rating of “Hold” and an average target price of $78.42.

Hologic Trading Up 0.1%

Shares of HOLX stock opened at $75.41 on Friday. The stock has a market cap of $16.83 billion, a P/E ratio of 31.42, a P/E/G ratio of 2.24 and a beta of 0.73. The company has a quick ratio of 3.32, a current ratio of 4.04 and a debt-to-equity ratio of 0.48. Hologic, Inc. has a fifty-two week low of $51.90 and a fifty-two week high of $75.75. The business has a fifty day simple moving average of $75.16 and a 200-day simple moving average of $72.93.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Thursday, January 29th. The medical equipment provider reported $1.04 EPS for the quarter, missing the consensus estimate of $1.09 by ($0.05). Hologic had a return on equity of 19.58% and a net margin of 13.18%.The business had revenue of $1.05 billion during the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter in the prior year, the firm earned $0.87 earnings per share. Hologic’s quarterly revenue was up 2.5% on a year-over-year basis. On average, analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Hologic Company Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.